Orchestra BioMed and Immunocore announce investor conference appearances

Orchestra BioMed Holdings Inc. and Immunocore Holdings plc have announced upcoming presentations at various investor conferences in September.

Orchestra BioMed will participate in the H. C. Wainwright 28th Annual Global Investment Conference on September 16. The company plans to discuss its two lead medical-device programs currently in pivotal clinical trials: Atrioventricular Interval Modulation Therapy (AVIM Therapy) for hypertension, developed in collaboration with Medtronic, and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease. Both technologies have received FDA Breakthrough Device Designations.

Immunocore, a biotechnology company specializing in TCR bispecific immunotherapies, will participate in several events throughout September, including the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Baird 2026 Global Healthcare Conference. The company focuses on its ImmTAX platform to treat cancer, infectious diseases, and autoimmune diseases.